Know Cancer

or
forgot password

Biomarker Analysis of Gastrointestinal, Genitourinary, Sarcoma, Rare Cancer


N/A
N/A
N/A
Open (Enrolling)
Both
Sarcoma

Thank you

Trial Information

Biomarker Analysis of Gastrointestinal, Genitourinary, Sarcoma, Rare Cancer


Inclusion Criteria:



1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare
cancer

2. Written informed consent

3. body fluid derived from cancer, available for drainage and collection

Exclusion Criteria:

- patients who do not give informed consent form for research use of
biomaterials/biospecimens

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Biomarker analyses to predict treatment response in metastatic cancer

Outcome Description:

Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.

Outcome Time Frame:

3 year

Safety Issue:

No

Authority:

South Korea: Korea Food and Drug Administration (KFDA)

Study ID:

2011-07-089-013

NCT ID:

NCT01831609

Start Date:

November 2011

Completion Date:

December 2016

Related Keywords:

  • Sarcoma
  • Gastrointestinal
  • Genitourinary
  • Rare Cancer
  • Sarcoma

Name

Location